Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sight SciencesSGHT -2.01%64 Equity-to-Asset is 0.50 as of Jun. 2026, which is 24% below its 10-year median of 0.66. GuruFocus rates SGHT with a GF Score™ of 64/100 and a GF Value™ of $4.63 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Sight Sciences ranks worse than 66.86% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sight Sciences's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $52.89 Mil. Sight Sciences's Total Assets for the quarter that ended in Jun. 2026 was $104.87 Mil.
Therefore, Sight Sciences's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.50.
The historical rank and industry rank for Sight Sciences's Equity-to-Asset or its related term are showing as below:
SGHT'
s Equity-to-Asset Range Over the Past 10 Years
Min: -3.58 Med: 0.66 Max: 0.85
Current: 0.5
During the past 8 years, the highest Equity to Asset Ratio of Sight Sciences was 0.85. The lowest was -3.58. And the median was 0.66.
SGHT's Equity-to-Asset is ranked worse than 66.86% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs SGHT: 0.50
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Sight Sciences Equity-to-Asset Related Terms
Sight Sciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Sight Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGHT vs TMCI, TLSI, SENS: Equity-to-Asset Comparison
For the Medical Devices subindustry, Sight Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Sight Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a Equity-to-Asset of 0.50 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sight Sciences and its competitors. This is 24% below median its historical median of 0.66. According to the industry distribution chart, Sight Sciences ranks #569 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 66.9%.
Is Sight Sciences' Equity-to-Asset too high?
Sight Sciences' current Equity-to-Asset of 0.50 is 24% below median its 10-year median of 0.66. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Sight Sciences' value of 0.50 is 21.9% below this industry median. Based on the distribution chart, Sight Sciences ranks #569 out of 851 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sight Sciences has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Equity-to-Asset compare to TMCI and TLSI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #569 out of 851 companies for Equity-to-Asset. This places Sight Sciences in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Sight Sciences' value of 0.50 is 21.9% below this benchmark. While the company's 10-year median is 0.66 vs. the industry median of 0.64, Sight Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current Equity-to-Asset of 0.50 is 21.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current Equity-to-Asset is 0.50, which is 24% below median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.63, compared to a current price of $8.30 — trading 79.3% above its estimated fair value. The current Equity-to-Asset is 0.50, which is 24% below median its 10-year median of 0.66 and 21.9% below the Medical Devices & Instruments industry median of 0.64. Sight Sciences' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Equity-to-Asset is 0.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $8.30 is trading 79.3% above its estimated GF Value™ of $4.63.
GuruFocus considers Sight Sciences to be Significantly Overvalued.
Key valuation signals for SGHT:
Equity-to-Asset: 0.50 (24% below median its 10-year median of 0.66)
GF Value™: $4.63 vs. price of $8.30 (79.3% above fair value)
Industry Position: 21.9% below the Medical Devices & Instruments median (#569 of 851)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
64GF Score
Get the complete analysis for SGHT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
